Progression from High Insulin Resistance to Type 2 Diabetes Does Not Entail Additional Visceral Adipose Tissue Inflammation

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Barbarroja, Nuria ^a,e   Lopez Pedrera, Chary ^b   Garrido Sanchez, Lourdes ^c   Mayas, Maria Dolores ^d   Oliva Olivera, Wilfredo ^a,e   Bernal Lopez, Maria Rosa ^a,e   El Bekay, Rajaa ^a,e   Tinahones, Francisco Jose ^a,e  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^d UNIVERSITY OF JAÉN   (Spain)

^e Instituto de Salud Carlos III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPID; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LEAN BODY WEIGHT; LIPID BLOOD LEVEL; MACROPHAGE; MALE; MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; SIGNAL TRANSDUCTION;

ADULT; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INFLAMMATION; INSULIN RESISTANCE; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTRA-ABDOMINAL FAT; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NF-KAPPA B; OBESITY, MORBID; STAT3 TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84868122221     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048155     Document Type: Article

References (42)

1. McKenney RL, Short DK, (2011) Tipping the balance: the pathophysiology of obesity and type 2 diabetes mellitus. Surg Clin North Am 91: 1139-48.
2. Donath MY, Böni-Schnetzler M, Ellingsgaard H, (2009) Ehses JA. Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes. Physiology (Bethesda) 24: 325-31.
3. Prentki M, Nolan CJ, (2006) Islet beta cell failure in type 2 diabetes. J Clin Invest 116: 1802-12.
4. Robertson RP, Harmon J, Tran PO, Poitout V, (2004) Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 53 (Suppl 1): S119-24.
5. Donath MY, Schumann DM, Faulenbach M, Ellingsgaard H, Perren A, et al. (2008) Islet inflammation in type 2 diabetes: from metabolic stress to therapy. Diabetes Care 31 (Suppl 2): S161-4.
6. Ehses JA, Ellingsgaard H, Böni-Schnetzler M, Donath MY, (2009) Pancreatic islet inflammation in type 2 diabetes: from alpha and beta cell compensation to dysfunction. Arch Physiol Biochem115: 240-7.
7. Gastaldelli A, Miyazaki Y, Pettiti M, Matsuda M, Mahankali S, et al. (2002) Metabolic effects of visceral fat accumulation in type 2 diabetes. J Clin Endocrinol Metab 87: 5098-103.
8. Skurk T, Alberti-Huber C, Herder C, (2007) Hauner H. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 92: 1023-33.
9. Morris DL, Singer K, Lumeng NC, (2011) Adipose tissue macrophages: phenotypic plasticity and diversity in lean and obese states. Curr Opin Clin Nutr Metab Care 14: 341-6.
10. Aguirre V, Uchida T, Yenush L, Davis R, White MF, (2000) The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 275: 9047-54.
11. Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, et al. (2002) Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem 277: 1531-7.
12. Gao Z, Hwang D, Bataille F, Lefevre M, York D, et al. (2002) Serine phosphorylation of insulin receptor substrate 1 by inhibitor kappa B kinase complex. J Biol Chem 277: 48115-21.
13. Engelman JA, Berg AH, Lewis RY, Lisanti MP, Scherer PE, (2000) Tumor necrosis factor alpha-mediated insulin resistance, but not dedifferentiation, is abrogated by MEK1/2 inhibitors in 3T3-L1 adipocytes. Mol Endocrinol 14: 1557-69.
14. Serrano-Marco L, Rodríguez-Calvo R, El Kochairi I, Palomer X, Michalik L, et al. (2011) Activation of peroxisome proliferator-activated receptor-beta/-delta (PPAR-beta/-delta) ameliorates insulin signaling and reduces SOCS3 levels by inhibiting STAT3 in interleukin-6-stimulated adipocytes. Diabetes 60: 1990-9.
15. Zlotnik A, Gruenbaum BF, Mohar B, Kuts R, Gruenbaum SE, et al. (2011) The effects of estrogen and progesterone on blood glutamate levels: evidence from changes of blood glutamate levels during the menstrual cycle in women. Biol Reprod 84: 581-6.
16. Knopp RH, Paramsothy P, Retzlaff BM, Fish B, Walden C, et al. (2006) Sex differences in lipoprotein metabolism and dietary response: basis in hormonal differences and implications for cardiovascular disease. Curr Cardiol Rep 8: 452-459.
17. Juge-Aubry CE, Somm E, Pernin A, Alizadeh N, Giusti V, et al. (2005) Adipose tissue is a regulated source of interleukin-10. Cytokine 29: 270-4.
18. Vallerie SN, Hotamisligil GS, (2010) The role of JNK proteins in metabolism. Sci Transl Med 2: 60rv5.
19. Sun H, Zhang Y, Gao P, Li Q, Sun Y, et al. (2011) Adiponectin reduces C-reactive protein expression and downregulates STAT3 phosphorylation induced by IL-6 in HepG2 cells. Mol Cell Biochem 347: 183-9.
20. Saltiel AR, Kahn CR, (2001) Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414: 799-806.
21. White MF, (2002) IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab 2002 283: E413-22.
22. Bal Y, Adas M, Helvaci A, (2010) Evaluation of the relationship between insulin resistance and plasma tumor necrosis factor-alpha, interleukin-6 and C-reactive protein levels in obese women. Bratisl Lek Listy 111: 200-4.
23. Poitout V, Robertson RP, (2008) Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev 29: 351-66.
24. Tanabe K, Liu Y, Hasan SD, Martinez SC, Cras-Méneur C, et al. (2011) Glucose and fatty acids synergize to promote B-cell apoptosis through activation of glycogen synthase kinase 3beta independent of JNK activation. PLoS One 6: e18146.
25. Barbarroja N, Lopez-Pedrera R, Mayas MD, García-Fuentes E, Garrido-Sánchez L, et al. (2010) The obese healthy paradox: is inflammation the answer? Biochem J 430: 141-9.
26. Tordjman J, Poitou C, Hugol D, Bouillot JL, Basdevant A, et al. (2009) Association between omental adipose tissue macrophages and liver histopathology in morbid obesity: influence of glycemic status. J Hepatol 51: 354-62.
27. Ugi S, Nishio Y, Yamamoto H, Ikeda K, Kobayashi M, et al. (2010) Relation of the expression of transcriptional factor TFAP2B to that of adipokines in subcutaneous and omental adipose tissues. Obesity 18: 1277-1282.
28. Samaras K, Botelho NK, Chisholm DJ, Lord RV, (2010) Subcutaneous and visceral adipose tissue gene expression of serum adipokines that predict type 2 diabetes. Obesity 18: 884-889.
29. Desprès JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, et al. (1990) Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 10: 497-511.
30. Misra A, Vikram NK, (2003) Clinical and pathophysiological consequences of abdominal adiposity and abdominal adipose tissue depots. Nutrition 19: 457-66.
31. Harman-Boehm I, Blüher M, Redel H, Sion-Vardy N, Ovadia S, et al. (2007) Macrophage infiltration into omental versus subcutaneous fat across different populations: effect of regional adiposity and the comorbidities of obesity. J Clin Endocrinol Metab 92: 2240-7.
32. Cancello R, Henegar C, Viguerie N, Taleb S, Poitou C, et al. (2005) Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 54: 2277-86.
33. Prieur X, Mok CY, Velagapudi VR, Núñez V, Fuentes L, et al. (2011) Differential lipid partitioning between adipocytes and tissue macrophages modulates macrophage lipotoxicity and M2/M1 polarization in obese mice. Diabetes 60: 797-809.
34. White MF, (2006) Regulating insulin signaling and beta-cell function through IRS proteins. Can J Physiol Pharmacol 84: 725-37.
35. Youngren JF, (2007) Regulation of insulin receptor function. Cell Mol Life Sci 64: 873-91.
36. Zhang X, Xu A, Chung SK, Cresser JH, Sweeney G, et al. (2011) Selective inactivation of c-Jun NH2-terminal kinase in adipose tissue protects against diet-induced obesity and improves insulin sensitivity in both liver and skeletal muscle in mice. Diabetes 60: 486-95.
37. Carlsen H, Haugen F, Zadelaar S, Kleemann R, Kooistra T, et al. (2009) Diet-induced obesity increases NF-kappaB signaling in reporter mice. Genes Nutr 4: 215-22.
38. Zick Y, (2001) Insulin resistance: a phosphorylation-based uncoupling of insulin signaling. Trends Cell Biol 11: 437-41.
39. Bendinelli P, Maroni P, Pecori Giraldi F, Piccoletti R, (2000) Leptin activates Stat3, Stat1 and AP-1 in mouse adipose tissue. Mol Cell Endocrinol 168: 11-20.
40. Bates SH, Stearns WH, Dundon TA, Schubert M, Tso AW, et al. (2003) STAT3 signalling is required for leptin regulation of energy balance but not reproduction. Nature 421: 856-9.
41. Jager J, Grémeaux T, Cormont M, Le Marchand-Brustel Y, Tanti JF, (2007) Interleukin-1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology 148: 241-51.
42. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-9.